NexgenRx Inc (TSE:NXG) has released an update.
NexgenRx Inc. has reported a strong financial performance for the year ended December 31, 2023, with a revenue increase of 8.33% from the previous year, reaching $13,846,329, and a solid EBITDA of $1,067,247. Despite challenging economic conditions, the company has maintained a robust cash position after paying dividends, signaling its ability to generate free cash flow. Celebrating its 20th anniversary, NexgenRx continues to innovate and expand its product solutions in the marketplace.
For further insights into TSE:NXG stock, check out TipRanks’ Stock Analysis page.
